Insider Buying: Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Purchases 1,403 Shares of Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) Director Angie You bought 1,403 shares of the business's stock in a transaction on Monday, June 23rd. The stock was bought at an average cost of $9.43 per share, with a total value of $13,230.29. Following the transaction, the director now owns 28,000 shares in the company, valued at $264,040. This trade represents a 5.28% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Angie You also recently made the following trade(s):

• On Friday, June 20th, Angie You purchased 26,597 shares of Oric Pharmaceuticals stock. The shares were purchased at an average price of $9.39 per share, for a total transaction of $249,745.83.

Oric Pharmaceuticals Trading Up 2.6%

Shares of NASDAQ ORIC traded up $0.27 during midday trading on Thursday, reaching $10.50. 1,739,709 shares of the stock were exchanged, compared to its average volume of 793,134. Oric Pharmaceuticals, Inc. has a 52-week low of $3.90 and a 52-week high of $14.67. The stock has a 50 day moving average price of $7.05 and a 200-day moving average price of $7.70. The company has a market capitalization of $894.81 million, a P/E ratio of -5.61 and a beta of 1.49.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09. On average, analysts forecast that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Institutional Trading of Oric Pharmaceuticals

A number of large investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new position in shares of Oric Pharmaceuticals in the fourth quarter worth about $50,000. Arizona State Retirement System bought a new position in shares of Oric Pharmaceuticals in the first quarter valued at approximately $56,000. BNP Paribas Financial Markets bought a new position in shares of Oric Pharmaceuticals in the fourth quarter valued at approximately $71,000. Hsbc Holdings PLC bought a new position in Oric Pharmaceuticals during the first quarter worth $102,000. Finally, PNC Financial Services Group Inc. increased its position in Oric Pharmaceuticals by 22.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock worth $109,000 after acquiring an additional 2,520 shares during the period. Institutional investors and hedge funds own 95.05% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on ORIC. Cantor Fitzgerald reissued an "overweight" rating on shares of Oric Pharmaceuticals in a report on Tuesday, May 6th. Guggenheim reiterated a "buy" rating on shares of Oric Pharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright reaffirmed a "buy" rating and set a $21.00 price objective on shares of Oric Pharmaceuticals in a research note on Monday, May 5th. JPMorgan Chase & Co. boosted their target price on shares of Oric Pharmaceuticals from $21.00 to $22.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, Wedbush restated an "outperform" rating and issued a $20.00 price objective on shares of Oric Pharmaceuticals in a report on Monday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Oric Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $19.17.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.